Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua Epstein

Showing results (31-40 of 85) with videos related to

Pageof 9
Sort By:
Cancer|May 13, 2008
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myelomaBart Barlogie, Elias Anaissie, Jeffrey Haessler, et al.
Blood|November 11, 2011
An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplificationOwen W Stephens, Qing Zhang, Pingping Qu, et al.
Blood|October 20, 2009
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myelomaLijuan Chen, Siqing Wang, Yiming Zhou, et al.
Hematology. American Society of Hematology. Education Program|November 25, 2003
Advances in biology and therapy of multiple myelomaSophie Barillé-Nion, Bart Barlogie, Régis Bataille, et al.
Haematologica|February 8, 2006
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse modelShmuel Yaccoby, Michele J Wezeman, Maurizio Zangari, et al.
British Journal of Haematology|August 26, 2009
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3John D Shaughnessy, Yiming Zhou, Jeff Haessler, et al.
Leukemia Research|July 27, 2023
Growth and dormancy control of myeloma cells by mesenchymal stem cellsSyed J Mehdi, Kalyan Ghatak, Wen Ling, et al.
Blood|October 30, 2016
MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myelomaYa-Wei Qiang, Shiqiao Ye, Yu Chen, et al.
Genes, Chromosomes & Cancer|July 30, 2015
Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpressionErming Tian, Magne Børset, Jeffrey R Sawyer, et al.
Blood|May 23, 2007
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myelomaJianfei Qian, Jin Xie, Sungyoul Hong, et al.
Pageof 9

Showing results (31-40 of 85) with videos related to

Sort By:
Pageof 9
Cancer|May 13, 2008
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myelomaBart Barlogie, Elias Anaissie, Jeffrey Haessler, et al.
Blood|November 11, 2011
An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplificationOwen W Stephens, Qing Zhang, Pingping Qu, et al.
Blood|October 20, 2009
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myelomaLijuan Chen, Siqing Wang, Yiming Zhou, et al.
Hematology. American Society of Hematology. Education Program|November 25, 2003
Advances in biology and therapy of multiple myelomaSophie Barillé-Nion, Bart Barlogie, Régis Bataille, et al.
Haematologica|February 8, 2006
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse modelShmuel Yaccoby, Michele J Wezeman, Maurizio Zangari, et al.
British Journal of Haematology|August 26, 2009
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3John D Shaughnessy, Yiming Zhou, Jeff Haessler, et al.
Leukemia Research|July 27, 2023
Growth and dormancy control of myeloma cells by mesenchymal stem cellsSyed J Mehdi, Kalyan Ghatak, Wen Ling, et al.
Blood|October 30, 2016
MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myelomaYa-Wei Qiang, Shiqiao Ye, Yu Chen, et al.
Genes, Chromosomes & Cancer|July 30, 2015
Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpressionErming Tian, Magne Børset, Jeffrey R Sawyer, et al.
Blood|May 23, 2007
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myelomaJianfei Qian, Jin Xie, Sungyoul Hong, et al.
Pageof 9